Development of models and detection methods for different forms of cytomegalovirus for the evaluation of viral inactivation agents

Transfusion

Volumn 46, Issue 9, 2006, Pages 1580-1588

  Jayarama, Vasudevacharya ^a,b   Marcello, Jennifer ^a   Ohagen, Asa ^a   Gibaja, Veronica ^a   Lunderville, Douglas ^a   Horrigan, Jeff ^a   Chapman, John ^a   Lazo, Aris ^a  

^a VI Technologies Inc   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; PEN 110; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOTOXICITY; ERYTHROCYTE; HUMAN; HUMAN CELL; IN VITRO STUDY; POLYMERASE CHAIN REACTION; TISSUE CULTURE; TISSUE CULTURE TECHNIQUE; VIRUS DETECTION; VIRUS INACTIVATION; VIRUS INFECTION; VIRUS TITRATION;

ANTIVIRAL AGENTS; BIOLOGICAL ASSAY; CELL LINE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; EVALUATION STUDIES; FIBROBLASTS; HUMANS; LUNG; POLYAMINES; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; VIRUS INACTIVATION; VIRUS LATENCY; VIRUS REPLICATION;

EID: 33748301975     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2006.00926.x     Document Type: Article

References (24)

1. Emery VC. Investigation of CMV disease in immunocompromised patients. J Clin Pathol 2001;54:84-8.
2. Griffiths PD, Clark DA, Emery VC. Betaherpesviruses in transplant recipients. J Antimicrob Chemother 2000;45 (Suppl T3):29-34.
3. de Jong MD, Galasso GJ, Gazzard B, et al. Summary of the II International Symposium on Cytomegalovirus. Antiviral Res 1998;39:141-62.
4. Pass RF, Burke RL. Development of cytomegalovirus vaccines: prospects for prevention of congenital CMV infection. Semin Pediatr Infect Dis 2002;13:196-204.
5. Grefte A, van der Giessen M, van Son W, The TH. Circulating cytomegalovirus (CMV)-infected endothelial cells in patients with an active CMV infection. J Infect Dis 1993;167:270-7.
6. Gerna G, Zipeto D, Percivalle E, et al. Human cytomegalovirus infection of the major leukocyte subpopulations and evidence for initial viral replication in polymorphonuclear leukocytes from viremic patients. J Infect Dis 1992;166:1236-44.
7. Soderberg-Naucler C, Fish KN, Nelson JA. Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors. Cell 1997;91:119-26.
8. Soderberg-Naucler C, Streblow DN, Fish KN, et al. Reactivation of latent human cytomegalovirus in CD14(+) monocytes is differentiation dependent. J Virol 2001;75:7543-54.
9. Taylor-Wiedeman J, Sissons P, Sinclair J. Induction of endogenous human cytomegalovirus gene expression after differentiation of monocytes from healthy carriers. J Virol 1994;68:1597-604.
10. Drew WL, Tegtmeier G, Alter HJ, et al. Frequency and duration of plasma CMV viremia in seroconverting blood donors and recipients. Transfusion 2003;43:309-13.
11. James DJ, Sikotra S, Sivakumaran M, et al. The presence of free infectious cytomegalovirus (CMV) in the plasma of donated CMV-seropositive blood and platelets. Transfus Med 1997;7:123-6.
12. Wolf DG, Spector SA. Early diagnosis of human cytomegalovirus disease in transplant recipients by DNA amplification in plasma. Transplantation 1993;56:330-4.
13. Chapman J. Progress in improving the pathogen safety of red cell concentrates. Vox Sang 2000;78:203-4.
14. Chapman J. Pathogen inactivation of red cell concentrates using Inactine chemistry. Transfus Apher Sci 2001;25:191-2.
15. Ohagen A, Gibaja V, Aytay S, et al. Inactivation of HIV in blood. Transfusion 2002;42:1308-17.
16. Lazo A, Tassello J, Jayarama V, et al. Broad-spectrum virus reduction in red cell concentrates using INACTINE PEN110 chemistry. Vox Sang 2002;83:313-23.
17. Aytay S, Ohagen A, Busch MR, et al. Development of a sensitive PCR inhibition method to demonstrate HBV nucleic acid inactivation. Transfusion 2004;44:476-84.
18. Weinshenker BG, Wilton S, Rice GP. Phorbol ester-induced differentiation permits productive human cytomegalovirus infection in a monocytic cell line. J Immunol 1988;140:1625-31.
19. West PG, Baker WW. Enhancement by calcium of the detection of cytomegalovirus in cells treated with dexamethasone and dimethyl sulfoxide. J Clin Microbiol 1990;28:1708-10.
20. Karber J. Beitrag zur kollectiven Behandlung pharmacologische Reihenversuche. Arch Exp Pathol Pharmakol 1931;162:480-3.
21. ICH topic Q 5 A. Quality of biotechnological products: viral safety evaluation of biotechnology products derived from cell lines of human or animal origin. [monograph on the Internet]. CPMP/ICH/295/95. London: Human Medicines Evaluation Unit, The European Agency for the Evaluation of Medicinal Products; 1997. Available from: http://www.emea.eu.int/pdfs/human/ich/029595en.pdf.
22. Taylor-Wiedeman J, Sissons JG, Borysiewicz LK, Sinclair JH. Monocytes are a major site of persistence of human cytomegalovirus in peripheral blood mononuclear cells. J Gen Virol 1991;72:2059-64.
23. Preiksaitis JK. Prevention of transfusion-acquired CMV infection: is there a role for NAT? Transfusion 2003;43:302-5.
24. Roback JD, Drew WL, Laycock ME, et al. CMV DNA is rarely detected in healthy blood donors using validated PCR assays. Transfusion 2003;43:314-21.